$11.4 Billion is the total value of Baker Brothers Advisors's 126 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 18.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $1,549,140,000 | +13.8% | 14,865,559 | +0.1% | 13.59% | +20.1% |
| SGEN | Buy | Seattle Genetics, Inc. | $1,494,121,000 | +46.4% | 30,870,262 | +6.9% | 13.11% | +54.4% |
| ALXN | New | Alexion Pharmaceuticals, Inc. | $1,182,706,000 | – | 6,542,599 | +100.0% | 10.37% | – |
| ABBV | New | AbbVie Inc. | $965,758,000 | – | 14,373,538 | +100.0% | 8.47% | – |
| ACAD | ACADIA Pharmaceuticals Inc. | $857,763,000 | +28.5% | 20,481,442 | 0.0% | 7.52% | +35.5% | |
| Incyte Corporation Notes 1.25% 11/15/2020 144Aconv bonds | $567,758,000 | +11.7% | 274,500,000 | 0.0% | 4.98% | +17.8% | ||
| BMRN | Sell | BioMarin Pharmaceutical Inc. | $560,148,000 | +7.0% | 4,095,247 | -2.5% | 4.91% | +12.8% |
| Incyte Corporation Notes 0.375% 11/15/2018 144Aconv bonds | $529,519,000 | +12.2% | 259,000,000 | 0.0% | 4.64% | +18.3% | ||
| Incyte Corporation Notes 4.75% 10/1/2015 144Aconv bonds | $478,833,000 | +13.6% | 40,446,000 | 0.0% | 4.20% | +19.8% | ||
| GHDX | Buy | Genomic Health Inc. | $379,545,000 | -9.0% | 13,657,598 | +0.0% | 3.33% | -4.1% |
| ANAC | Sell | Anacor Pharmaceuticals, Inc. | $280,722,000 | +15.4% | 3,625,498 | -13.8% | 2.46% | +21.7% |
| DYAX | Buy | Dyax Corp. | $210,056,000 | +108.2% | 7,926,630 | +31.6% | 1.84% | +119.7% |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $172,849,000 | +82.7% | 11,577,299 | +10.5% | 1.52% | +92.6% |
| BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017conv bonds | $149,970,000 | +9.5% | 22,379,000 | 0.0% | 1.32% | +15.5% | ||
| Gilead, Inc. 1.625% 5/1/16conv bonds | $107,926,000 | +19.7% | 20,944,000 | 0.0% | 0.95% | +26.3% | ||
| NVTA | Invitae Corporation | $97,538,000 | -11.2% | 6,554,967 | 0.0% | 0.86% | -6.3% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $89,134,000 | -8.2% | 4,190,594 | 0.0% | 0.78% | -3.2% | |
| MRTX | Mirati Therapeutics, Inc. | $88,276,000 | +7.3% | 2,805,074 | 0.0% | 0.77% | +13.2% | |
| HRTX | Buy | Heron Therapeutics, Inc. | $87,491,000 | +130.6% | 2,807,784 | +7.7% | 0.77% | +142.7% |
| ONCE | Sell | Spark Therapeutics, Inc. | $76,084,000 | -26.0% | 1,262,382 | -4.9% | 0.67% | -22.1% |
| Medivation, Inc. 2.625% 4/1/17conv bonds | $75,011,000 | -11.7% | 33,889,000 | 0.0% | 0.66% | -6.8% | ||
| CERS | Cerus Corporation | $70,341,000 | +24.5% | 13,553,275 | 0.0% | 0.62% | +31.3% | |
| Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021conv bonds | $60,049,000 | -1.2% | 59,583,000 | 0.0% | 0.53% | +4.4% | ||
| XOMA | Sell | XOMA Corporation | $56,972,000 | +6.4% | 14,683,513 | -0.2% | 0.50% | +12.4% |
| DBVT | Buy | DBV Technologies S.A.sponsored adr | $55,451,000 | +56.2% | 1,862,019 | +22.6% | 0.49% | +64.7% |
| VSAR | Buy | Versartis, Inc. | $52,305,000 | -4.4% | 3,436,585 | +15.4% | 0.46% | +0.9% |
| ALDR | Buy | Alder Biopharmaceuticals Inc. | $47,233,000 | +86.1% | 891,688 | +1.4% | 0.41% | +96.2% |
| HALO | Sell | Halozyme Therapeutics, Inc. | $43,603,000 | +35.8% | 1,931,057 | -14.1% | 0.38% | +43.1% |
| LIFE | New | aTyr Pharma Inc. | $43,247,000 | – | 2,335,125 | +100.0% | 0.38% | – |
| XNPT | XenoPort, Inc. | $39,898,000 | -13.9% | 6,508,622 | 0.0% | 0.35% | -9.1% | |
| ARRY | Sell | Array BioPharma Inc. | $39,529,000 | -5.2% | 5,482,505 | -3.1% | 0.35% | 0.0% |
| INSM | Insmed, Inc. | $38,669,000 | +17.4% | 1,583,490 | 0.0% | 0.34% | +23.7% | |
| SGMO | Buy | Sangamo BioSciences, Inc. | $35,831,000 | +62.7% | 3,230,932 | +130.0% | 0.31% | +71.6% |
| IMGN | Buy | ImmunoGen, Inc. | $33,368,000 | +273.0% | 2,320,424 | +132.2% | 0.29% | +295.9% |
| TGTX | Sell | TG Therapeutics, Inc. | $33,246,000 | +4.7% | 2,003,991 | -2.3% | 0.29% | +10.6% |
| PGNX | Progenics Pharmaceuticals, Inc. | $32,457,000 | +24.7% | 4,350,808 | 0.0% | 0.28% | +31.9% | |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $30,296,000 | -7.5% | 7,335,692 | -3.0% | 0.27% | -2.2% |
| GILD | Gilead Sciences, Inc. | $29,269,000 | +19.3% | 249,995 | 0.0% | 0.26% | +26.0% | |
| KYTH | Buy | Kythera Biopharmaceuticals, Inc. | $29,201,000 | +64.4% | 387,741 | +9.4% | 0.26% | +73.0% |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $25,862,000 | +0.1% | 6,970,902 | +0.1% | 0.23% | +5.6% |
| NBIX | Neurocrine Biosciences, Inc. | $25,897,000 | +20.3% | 542,236 | 0.0% | 0.23% | +26.8% | |
| BLUE | Buy | bluebird bio, Inc. | $25,442,000 | +43.7% | 151,105 | +3.1% | 0.22% | +51.7% |
| DSCI | Derma Sciences, Inc. | $24,758,000 | -15.5% | 3,457,841 | 0.0% | 0.22% | -11.1% | |
| ACOR | Acorda Therapeutics, Inc. | $24,628,000 | +0.2% | 738,916 | 0.0% | 0.22% | +5.4% | |
| NVAX | Novavax, Inc. | $21,675,000 | +34.7% | 1,945,687 | 0.0% | 0.19% | +41.8% | |
| FOMX | Buy | Foamix Pharmaceuticals Ltd. | $20,981,000 | +24.5% | 2,046,967 | +12.3% | 0.18% | +31.4% |
| XNCR | Xencor, Inc. | $19,159,000 | +43.4% | 872,072 | 0.0% | 0.17% | +51.4% | |
| GLPG | New | Galapagos NVsponsored adr | $19,018,000 | – | 369,276 | +100.0% | 0.17% | – |
| BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018conv bonds | $18,940,000 | +5.4% | 12,228,000 | 0.0% | 0.17% | +11.4% | ||
| CLVS | Clovis Oncology, Inc. | $17,807,000 | +18.4% | 202,630 | 0.0% | 0.16% | +24.8% | |
| OMER | Buy | Omeros Corporation | $17,354,000 | +23.6% | 964,621 | +51.3% | 0.15% | +29.9% |
| ZGNX | Buy | Zogenix, Inc. | $16,848,000 | +435.0% | 10,028,564 | +336.3% | 0.15% | +469.2% |
| LBIO | Buy | Lion Biotechnologies, Inc. | $16,666,000 | +3.9% | 1,817,429 | +37.2% | 0.15% | +9.8% |
| PRQR | Buy | ProQR Therapeutics N.V. | $16,475,000 | +88.2% | 988,299 | +147.1% | 0.14% | +98.6% |
| RPRX | Sell | Repros Therapeutics Inc. | $13,985,000 | -18.6% | 1,955,944 | -2.2% | 0.12% | -14.0% |
| ACHN | Buy | Achillion Pharmaceuticals, Inc. | $13,500,000 | +539.2% | 1,523,739 | +611.2% | 0.12% | +555.6% |
| RARE | Sell | Ultragenyx Pharmaceuticals | $12,686,000 | +37.2% | 123,894 | -16.8% | 0.11% | +44.2% |
| THLD | Threshold Pharmaceuticals, Inc. | $11,819,000 | -0.5% | 2,925,519 | 0.0% | 0.10% | +5.1% | |
| ADHD | Alcobra Ltd. | $11,706,000 | +16.2% | 1,789,871 | 0.0% | 0.10% | +22.6% | |
| MGNX | MacroGenics, Inc. | $11,582,000 | +21.0% | 305,043 | 0.0% | 0.10% | +27.5% | |
| AGIO | Sell | Agios Pharmaceuticals, Inc. | $11,114,000 | -21.4% | 100,000 | -33.3% | 0.10% | -17.8% |
| LJPC | La Jolla Pharmaceutical Company | $10,098,000 | +33.9% | 412,008 | 0.0% | 0.09% | +41.3% | |
| ZFGN | Buy | Zafgen, Inc. | $9,962,000 | +165.4% | 287,677 | +203.6% | 0.09% | +180.6% |
| OSIR | Osiris Therapeutics, Inc. | $9,714,000 | +10.7% | 499,193 | 0.0% | 0.08% | +16.4% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $9,632,000 | +22.9% | 3,200,000 | 0.0% | 0.08% | +29.2% | |
| RXDX | Ignyta, Inc. | $8,616,000 | +51.7% | 571,000 | 0.0% | 0.08% | +61.7% | |
| AQXP | Buy | Aquinox Pharmaceuticals, Inc. | $8,310,000 | -14.9% | 1,197,366 | +0.8% | 0.07% | -9.9% |
| SAGE | Buy | Sage Therapeutics, Inc. | $7,665,000 | +103.5% | 105,000 | +40.0% | 0.07% | +116.1% |
| LGND | Ligand Pharmaceuticals Incorporated | $7,405,000 | +30.9% | 73,386 | 0.0% | 0.06% | +38.3% | |
| CNCE | Concert Pharmaceuticals, Inc. | $7,384,000 | -1.7% | 495,908 | 0.0% | 0.06% | +4.8% | |
| ARWR | Sell | Arrowhead Research Corp. | $7,218,000 | -17.3% | 1,009,509 | -21.8% | 0.06% | -13.7% |
| KPTI | Karyopharm Therapeutics Inc. | $5,904,000 | -11.1% | 216,990 | 0.0% | 0.05% | -5.5% | |
| EPZM | Epizyme, Inc. | $5,580,000 | +27.8% | 232,481 | 0.0% | 0.05% | +36.1% | |
| AMRN | Amarin Corporation plcsponsored adr | $5,426,000 | +5.1% | 2,205,710 | 0.0% | 0.05% | +11.6% | |
| CMRX | Chimerix, Inc. | $5,323,000 | +22.6% | 115,216 | 0.0% | 0.05% | +30.6% | |
| AFMD | Affimed N.V. | $5,388,000 | +113.8% | 400,000 | 0.0% | 0.05% | +123.8% | |
| VNDA | Sell | Vanda Pharmaceuticals Inc. | $5,201,000 | -68.0% | 409,881 | -76.6% | 0.05% | -65.9% |
| AERI | Aerie Pharmaceuticals, Inc. | $5,284,000 | -43.7% | 299,356 | 0.0% | 0.05% | -41.0% | |
| MCRB | New | Seres Therapeutics, Inc. | $5,188,000 | – | 125,000 | +100.0% | 0.05% | – |
| CYTR | CytRx Corporation | $4,910,000 | +10.4% | 1,319,989 | 0.0% | 0.04% | +16.2% | |
| ASMB | Assembly Biosciences, Inc. | $4,815,000 | +45.5% | 250,000 | 0.0% | 0.04% | +50.0% | |
| RCPT | Receptos, Inc. | $4,542,000 | +15.2% | 23,900 | 0.0% | 0.04% | +21.2% | |
| JUNO | Sell | Juno Therapeutics, Inc. | $4,266,000 | -29.7% | 80,000 | -20.0% | 0.04% | -26.0% |
| STML | Stemline Therapeutics, Inc. | $3,925,000 | -18.7% | 333,497 | 0.0% | 0.03% | -15.0% | |
| NeuroDerm Ltd. | $3,838,000 | +14.4% | 250,000 | 0.0% | 0.03% | +21.4% | ||
| Array BioPharma Inc. Notes 3.0% 6/1/2020conv bonds | $3,780,000 | +0.6% | 3,000,000 | 0.0% | 0.03% | +6.5% | ||
| CRIS | New | Curis, Inc. | $3,567,000 | – | 1,077,663 | +100.0% | 0.03% | – |
| ENTA | Enanta Pharmaceuticals, Inc. | $3,390,000 | +46.9% | 75,357 | 0.0% | 0.03% | +57.9% | |
| ISIS | Isis Pharmaceuticals, Inc. | $3,288,000 | -9.6% | 57,140 | 0.0% | 0.03% | -3.3% | |
| ITCI | Intra-Cellular Therapies, Inc. | $3,328,000 | +33.8% | 104,166 | 0.0% | 0.03% | +38.1% | |
| PRTO | Buy | Proteon Therapeutics, Inc. | $3,157,000 | +57.0% | 176,762 | +2.2% | 0.03% | +64.7% |
| IMDZ | New | Immune Design Corp. | $3,076,000 | – | 148,937 | +100.0% | 0.03% | – |
| VTAE | Vitae Pharmaceuticals, Inc. | $2,701,000 | +22.9% | 187,597 | 0.0% | 0.02% | +33.3% | |
| BLPH | Bellerophon Therapeutics, Inc. | $2,776,000 | -13.6% | 350,000 | 0.0% | 0.02% | -11.1% | |
| Sell | Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18conv bonds | $2,606,000 | -0.2% | 3,423,000 | -2.2% | 0.02% | +4.5% | |
| DSCO | Discovery Laboratories, Inc. | $2,427,000 | -42.9% | 3,569,643 | 0.0% | 0.02% | -40.0% | |
| ZIOP | ZIOPHARM Oncology, Inc. | $2,271,000 | +11.4% | 189,259 | 0.0% | 0.02% | +17.6% | |
| MSTX | Mast Therapeutics, Inc. | $2,307,000 | +1.1% | 4,707,464 | 0.0% | 0.02% | +5.3% | |
| MRNS | Marinus Pharmaceuticals, Inc. | $2,320,000 | +29.0% | 200,000 | 0.0% | 0.02% | +33.3% | |
| TKMR | Tekmira Pharmaceuticals Corp. | $2,142,000 | -32.1% | 180,582 | 0.0% | 0.02% | -26.9% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $2,130,000 | -31.7% | 711,499 | 0.0% | 0.02% | -26.9% | |
| IRWD | Ironwood Pharmaceuticals, Inc. | $2,040,000 | -24.6% | 169,163 | 0.0% | 0.02% | -21.7% | |
| PTN | Palatin Technologies, Inc. | $1,825,000 | -12.7% | 2,050,000 | 0.0% | 0.02% | -5.9% | |
| OPHT | Ophthotech Corporation | $1,856,000 | +11.9% | 35,649 | 0.0% | 0.02% | +14.3% | |
| ADAP | New | Adaptimmune Therapeutics plcsponsored adr | $1,833,000 | – | 100,000 | +100.0% | 0.02% | – |
| LOXO | Loxo Oncology, Inc. | $1,803,000 | +44.8% | 100,000 | 0.0% | 0.02% | +60.0% | |
| CLLS | Cellectis S.A.sponsored adr | $1,804,000 | +4.3% | 50,000 | 0.0% | 0.02% | +14.3% | |
| RTTR | New | Ritter Pharmaceuticals, Inc. | $1,780,000 | – | 400,000 | +100.0% | 0.02% | – |
| ASND | Ascendis Pharma A/Ssponsored adr | $1,768,000 | +1.9% | 100,000 | 0.0% | 0.02% | +14.3% | |
| BDSI | Sell | BioDelivery Sciences International, Inc. | $1,672,000 | -37.8% | 210,021 | -17.9% | 0.02% | -31.8% |
| DERM | Dermira, Inc. | $1,755,000 | +14.3% | 100,000 | 0.0% | 0.02% | +15.4% | |
| BOTA | Sell | Biota Pharmaceuticals, Inc. | $1,719,000 | -13.4% | 830,440 | -3.8% | 0.02% | -11.8% |
| MDWD | MediWound Ltd. | $1,591,000 | -2.3% | 225,000 | 0.0% | 0.01% | 0.0% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $1,359,000 | +14.8% | 11,340 | 0.0% | 0.01% | +20.0% | |
| TENX | New | Tenax Therapeutics Inc. | $1,311,000 | – | 355,348 | +100.0% | 0.01% | – |
| ALDX | Aldeyra Therapeutics, Inc. | $1,102,000 | -23.8% | 142,000 | 0.0% | 0.01% | -16.7% | |
| OHRP | Ohr Pharmaceuticals, Inc. | $930,000 | -1.2% | 370,370 | 0.0% | 0.01% | 0.0% | |
| XLRN | Acceleron Pharma, Inc. | $910,000 | -16.9% | 28,765 | 0.0% | 0.01% | -11.1% | |
| QURE | UniQure B.V. | $810,000 | +11.0% | 30,000 | 0.0% | 0.01% | +16.7% | |
| FMI | Sell | Foundation Medicine, Inc. | $707,000 | -88.2% | 20,892 | -83.2% | 0.01% | -88.0% |
| AKAOQ | Achaogen, Inc. | $603,000 | -38.2% | 100,000 | 0.0% | 0.01% | -37.5% | |
| FPRX | Five Prime Therapeutics, Inc. | $478,000 | +8.6% | 19,247 | 0.0% | 0.00% | 0.0% | |
| CCXI | ChemoCentryx, Inc. | $404,000 | +9.2% | 49,064 | 0.0% | 0.00% | +33.3% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc. Pfd. Conv. Ex 6%pfd conv ex 6% | $85,000 | -1.2% | 13,253 | 0.0% | 0.00% | 0.0% | |
| Aptose Biosciences, Inc. | $170,000 | -6.1% | 33,397 | 0.0% | 0.00% | -50.0% | ||
| BTXWS | BioTime, Inc. Rightswarrants | $23,000 | -42.5% | 20,084 | 0.0% | 0.00% | – | |
| BIOD | Exit | Biodel Inc. | $0 | – | -30,179 | -100.0% | 0.00% | – |
| AEGR | Exit | Aegerion Pharmaceuticals, Inc. | $0 | – | -14,300 | -100.0% | -0.00% | – |
| SNTA | Exit | Synta Pharmaceuticals Corp. | $0 | – | -489,053 | -100.0% | -0.01% | – |
| RIGL | Exit | Rigel Pharmaceuticals Inc. | $0 | – | -357,187 | -100.0% | -0.01% | – |
| OSUR | Exit | Orasure Technologies Inc. | $0 | – | -229,397 | -100.0% | -0.01% | – |
| ASPX | Exit | Auspex Pharmaceuticals, Inc. | $0 | – | -25,000 | -100.0% | -0.02% | – |
| LPCN | Exit | Lipocine Inc. | $0 | – | -489,175 | -100.0% | -0.03% | – |
| INFI | Exit | Infinity Pharmaceuticals Inc. | $0 | – | -305,037 | -100.0% | -0.04% | – |
| TTHI | Exit | Transition Therapeutics, Inc. | $0 | – | -769,230 | -100.0% | -0.04% | – |
| CLDN | Exit | Celladon Corp | $0 | – | -366,806 | -100.0% | -0.06% | – |
| Exit | Salix Pharmaceuticals Inc. 1.5% 3/15/19conv bonds | $0 | – | -14,668,000 | -100.0% | -0.32% | – | |
| Exit | Salix Pharmaceuticals Inc. 2.75% 5/15/15conv bonds | $0 | – | -216,077,000 | -100.0% | -6.66% | – | |
| GEVA | Exit | Synageva Biopharma Corp. | $0 | – | -11,660,432 | -100.0% | -9.46% | – |
| PCYC | Exit | Pharmacyclics Inc. | $0 | – | -9,039,652 | -100.0% | -19.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.